Peripheral oxytocin treatment ameliorates obesity by reducing food intake and visceral fat mass
Peripheral oxytocin treatment ameliorates obesity by reducing food intake and visceral fat mass
复制标题
DOI：
10.18632/aging.100408
复制
发表时间：
2011-12-01
期刊：
影响因子：
5.2
通讯作者：
Yada, Toshihiko
中科院分区：
文献类型：
--
作者：
Maejima, Yuko;Iwasaki, Yusaku;Yada, Toshihiko
最近的研究表明，催产素(Oxt)与能量代谢有关。我们的目的是探讨不同途径外周OXT治疗对食物摄入量和能量平衡的急性和亚慢性影响。小鼠腹腔注射奥昔洛韦(OXT)可浓度依赖性地减少摄食量。Ip oxt注射诱导c-Fos在下丘脑和脑干包括弓状核(ARC)、室旁核(PVN)和孤束核(NTS)表达。皮下注射OXT抑制正常和高脂饮食诱导的肥胖(DIO)小鼠的食物摄入量。DIO小鼠每日皮下注射OXT 17天，在整个治疗期间和终止OXT后的额外9天内减少摄食量6天和体重。在DIO小鼠中，皮下注射渗透压微泵13天后输注OXT可减少摄食量、体重、内脏脂肪质量和脂肪细胞大小。OXT还能降低DIO小鼠的呼吸商，改善脂肪肝和糖耐量异常，但不影响正常血压。这些结果表明，外周OXT治疗减少了食物摄入量和内脏脂肪质量，并改善了肥胖、脂肪肝和糖耐量异常。外周OXT治疗为治疗肥胖和吞噬功能亢进提供了新的治疗途径。
Recent studies suggest that oxytocin (Oxt) is implicated in energy metabolism. We aimed to explore acute and sub-chronic effects of peripheral Oxt treatment via different routes on food intake and energy balance. Intraperitoneal (ip) injection of Oxt concentration-dependently decreased food intake in mice. Ip Oxt injection induced c-Fos expression in the hypothalamus and brain stem including arcuate nucleus (ARC), paraventricular nucleus (PVN) and nucleus tractus solitarius (NTS). Subcutaneous (sc) injection of Oxt suppressed food intake in normal and high fat diet-induced obese (DIO) mice. Daily sc injection of Oxt for 17 days in DIO mice reduced food intake for 6 days and body weight for the entire treatment period and additional 9 days after terminating Oxt. Oxt infusion by sc implanted osmotic minipumps for 13 days in DIO mice reduced food intake, body weight, and visceral fat mass and adipocyte size. Oxt infusion also decreased respiratory quotient specifically in light phase, ameliorated fatty liver and glucose intolerance, without affecting normal blood pressure in DIO mice. These results demonstrate that peripheral Oxt treatment reduces food intake and visceral fat mass, and ameliorates obesity, fatty liver and glucose intolerance. Peripheral Oxt treatment provides a new therapeutic avenue for treating obesity and hyperphagia.